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We conducted a randomized, double-blind, placebo-controlled, multicenter trial in 246 patients undergoing major elective pancreatic surgery. Patients were stratified into a high-risk stratum (limited to patients with pancreatic and periampullary tumors) or low-risk stratum (patients with chronic pancreatitis). Patients received octreotide (3 100 tg) or placebo subcutaneously for 7 days perioperatively. Eleven complications were defined" death, leakage of anastomosis, pancreatic fistula, abscess, fluid collection, shock, sepsis, bleeding, pulmonary insufficiency, renal insufficiency, and postoperative pancreatitis.
Two hundred patients underwent pancreatic head resection, 31 patients underwent left resection, and 15 patients had other procedures. The overall mortality rate within 90 days was 4.5%, with 3.2% in the octreotide group and 5.8% in the placebo group. The Table  3 , the only one of all the complications which was not reduced in the octreotide group of patients was bleeding.
On the subject of complications, 40 of the 246 patients had pancreatic duct occlusion with Ethibloc and they had a higher rate of fistula formation, but there is no breakdown anywhere in the paper to determine whether octreotide seemed to be beneficial or not for that subgroup.
One omission from the study is the description of what were considered standard prophylactic measures against the development of post-operative pulmonary embolism. Was there a standard protocol for this? This may be of some importance, especially when one considers that blood loss appeared to be a greater problem in the octreotide group. If heparin prophylaxis was standard, then the sporadic interaction between somatostatin and heparin may be a matter warranting consideration.
Overall the study is very impressive and the conclusion that octreotide be given to all patients undergoing high risk pancreatic surgery is a reasonable one. 
